Aethlon Medical, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
AEMD Nasdaq 3840 www.aethlonmedical.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aethlon Medical, Inc.

Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream - Jul 15th, 2026 5:00 am
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier® - Jul 13th, 2026 6:01 am
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - Jul 6th, 2026 7:25 am
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier® - Jun 26th, 2026 6:01 am
Aethlon Medical advances Hemopurifier study as final trial cohort nears completion - Jun 17th, 2026 10:18 am
Aethlon Medical Inc (AEMD) Q4 2026 Earnings Call Highlights: Strategic Advances Amid Financial ... - Jun 16th, 2026 7:00 pm
AEMD: Clinical Study Advances to Final Cohort; Preclinical Activities Expand - Jun 11th, 2026 9:18 am
Aethlon (AEMD) Q4 2026 Earnings Transcript - Jun 10th, 2026 4:15 pm
Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update - Jun 10th, 2026 2:15 pm
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026 - Jun 2nd, 2026 6:01 am
Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness - May 21st, 2026 6:01 am
AEMD: Hitting Key Milestones as Company Advances Clinical Study - Mar 24th, 2026 7:54 am
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review - Mar 24th, 2026 6:01 am
OTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCR - Mar 18th, 2026 9:46 am
AEMD: Positive Takeaways From CEO Chat - Mar 18th, 2026 8:24 am
Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives - Mar 13th, 2026 10:02 am
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Mar 13th, 2026 6:35 am
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities - Mar 12th, 2026 6:01 am
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - Mar 10th, 2026 8:21 am
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th - Mar 6th, 2026 6:35 am